Effect of astragaloside IV on osteogenic differentiation of BMSCs in osteoporotic rats via regulation of miR-21 and inhibition of the Notch signaling pathway.
10.11817/j.issn.1672-7347.2025.240427
- Author:
Jingjing XIAO
1
,
2
;
Xiaolan LIU
3
;
Jianying HUANG
3
;
Ben DOU
4
Author Information
1. First Department of Orthopedics and Traumatology, Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410008, China. 17673631326@
2. com.
3. First Department of Orthopedics and Traumatology, Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410008, China.
4. First Department of Orthopedics and Traumatology, Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410008, China. 20301256@qq.com.
- Publication Type:Journal Article
- Keywords:
Notch signaling pathway;
astragaloside IV;
bone marrow mesenchymal stem cells;
osteogenic differentiation;
osteoporosis
- MeSH:
Animals;
Triterpenes/pharmacology*;
Saponins/pharmacology*;
Osteogenesis/drug effects*;
MicroRNAs/metabolism*;
Rats, Sprague-Dawley;
Female;
Cell Differentiation/drug effects*;
Mesenchymal Stem Cells/drug effects*;
Signal Transduction/drug effects*;
Osteoporosis/pathology*;
Rats;
Cells, Cultured;
Receptor, Notch2/metabolism*;
Receptors, Notch/metabolism*;
Ovariectomy;
Cell Proliferation/drug effects*
- From:
Journal of Central South University(Medical Sciences)
2025;50(7):1126-1136
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:The core pathology of osteoporosis lies in bone resorption exceeding bone formation; thus, promoting osteogenesis is a key therapeutic strategy. The osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) forms the biological basis of bone formation. Astragaloside IV (A-IV), a major active component of Astragalus membranaceus, is known to enhance osteogenesis, but its precise molecular mechanisms remain unclear. This study aims to investigate the effects of A-IV on the proliferation and osteogenic differentiation of BMSCs from osteoporotic rats and to elucidate its molecular mechanism through the regulation of microRNA-21 (miR-21) and Notch2 expression.
METHODS:After 1 week of adaptive feeding, mature female SD rats were randomly divided into a sham-operated (Sham) group (n=4) and an ovariectomized (OVX) group (n=8) to establish an osteoporosis model. Twelve weeks after surgery, BMSCs were isolated from femoral bone marrow and cultured. Cells were divided into a S-BMSCs group (from Sham), an O-BMSCs group (from OVX), and an A-BMSCs group (from OVX-derived BMSCs treated with A-IV). S-BMSCs and O-BMSCs were induced for osteogenic differentiation using osteogenic induction medium, whereas A-BMSCs were treated with A-IV before induction. Flow cytometry was used to identify mesenchymal stem cell surface markers (CD29) and hematopoietic stem cell marker (CD34) to confirm BMSC characteristics. Cell proliferation was assessed using the methyl thiazolyl tetrazolium (MTT) assay. Alizarin red staining was performed to quantify calcium nodule formation, and alkaline phosphatase (ALP) activity assays were used to evaluate osteogenic differentiation. Real-time reverse transcription PCR (real-time RT-PCR) was used to detect changes in osteogenic-related genes, runt-related transcription factor 2 (Runx2) and osteopontin (OPN), as well as miR-21 expression. Western blotting was performed to assess Runx2, OPN, and Notch2 protein expression.
RESULTS:Flow cytometry confirmed that O-BMSCs retained the phenotypic characteristics of mesenchymal stem cells. A-IV significantly enhanced the proliferation of BMSCs from osteoporotic rats (P<0.05), increased ALP activity, and upregulated the mRNA and protein expression of Runx2 and OPN (P<0.05). Bioinformatic and experimental analyses demonstrated that miR-21 directly targeted Notch2. A-IV treatment increased miR-21 expression while suppressing Notch2 protein expression and inhibiting activation of the Notch signaling pathway (P<0.05).
CONCLUSIONS:Astragaloside IV promotes the osteogenic differentiation of BMSCs derived from osteoporotic rats by upregulating miR-21 expression and inhibiting the key Notch signaling protein Notch2, thereby relieving the Notch2-mediated suppression of osteogenesis.
